Efficacy and Safety of a Purified Standardised Bee Venom Preparation

This study is ongoing, but not recruiting participants.

First Received on December 9, 2005. Last Updated on February 10, 2012 History of Changes

Sponsor:	Allergopharma Joachim Ganzer KG
Information provided by (Responsible Party):	Allergopharma Joachim Ganzer KG
ClinicalTrials.gov Identifier:	NCT00263952

Purpose

The trial is performed to assess efficacy and safety of a purified standardised bee venom preparation in bee venom allergy

Condition	Intervention	Phase
Bee Venom Allergy	Biological: bee venom	Phase III

Study Type:	Interventional
Study Design:	Allocation: Non-Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment
Official Title:	Immunotherapy of Bee Venom Allergy: Evaluation of a New Purified Bee Venom Preparation in Comparison With Already Published Studies.

Resource links provided by NLM:

MedlinePlus related topics: Allergy

U.S. FDA Resources

Further study details as provided by Allergopharma Joachim Ganzer KG:

Study Start Date:	March 2003
Estimated Study Completion Date:	April 2010

Eligibility

Criteria

Inclusion Criteria:

Exclusion Criteria:

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00263952

Locations

Germany
Allergopharma Joachim Ganzer KG
Reinbek, Germany, 21465

Sponsors and Collaborators

Allergopharma Joachim Ganzer KG

Investigators

Principal Investigator:

Annemie Narkus, M.D.

More Information

Additional Information:

Leader in specific allergy research and therapy This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party:	Allergopharma Joachim Ganzer KG
ClinicalTrials.gov Identifier:	NCT00263952 History of Changes
Other Study ID Numbers:	Al0202ig
Study First Received:	December 9, 2005
Last Updated:	February 10, 2012
Health Authority:	Germany: Paul-Ehrlich-Institut

Keywords provided by Allergopharma Joachim Ganzer KG:

Bee venom allergy
Specific immunotherapy

Additional relevant MeSH terms:

Hypersensitivity
Immune System Diseases

ClinicalTrials.gov processed this record on February 12, 2012